Five Thousand Six Hundred Patents and a 510(k)Narrow moat

Intuitive Surgical (ISRG) — moat facet

A very large patent estate protecting products cleared on the lowest regulatory pathway there is.

Intuitive owned more than 5,600 patents granted and still in force and more than 2,500 pending worldwide at the end of 20251. It is one of the largest estates in medical devices and it took twenty-seven years to build.

The intellectual property position5,600+patents grantedand in force2,500+applications pendingClass IIthe regulatorypathway1,231da Vinci 5systems installed870 of 2025's 1,721 placements were da Vinci 5, against 362 in 2024.
A very large estate protecting a product cleared on the lowest regulatory pathway there is. Both halves of that sentence are true at once.

It is also the facet of the moat that is most obviously finite, and Intuitive says so in its own words: "Patents have finite terms. The expiration of a patent ends the exclusive rights accorded by the patent for the invention claimed." The foundational patents on wristed instruments and the master-slave console architecture date from the 1990s and are long expired, which is precisely why fourteen companies now appear in the competition disclosure.

The regulatory position is weaker than the estate suggests. Intuitive's products are Class II medical devices cleared under section 510(k) of the Federal Food, Drug, and Cosmetic Act, which requires a manufacturer to demonstrate that its device is "substantially equivalent" to a legally marketed predicate2. That is not the approval regime that protects a drug; it is a pathway explicitly designed to let comparable products onto the market. Every rival that clears it does so partly by pointing at a da Vinci.

What the patents and the twenty-seven years actually buy is harder to name and more durable: the accumulated engineering of instrument wrists, cable drives, energy delivery, stapling, imaging and control software, plus the clinical evidence base and the regulatory clearances for specific procedures in specific countries — a list Intuitive has been extending one indication at a time for two decades. A competitor with a working robot still has to obtain clearance for each procedure in each market, and then generate the evidence that persuades a surgeon to use it.

The current expression of it is da Vinci 5, cleared by the FDA in March 2024 for all specialties indicated for da Vinci Xi except cardiac and pediatric, with more than 10,000 times the computing power of its predecessor and force-feedback instruments that measure the force applied to tissue3. The installed base reached 1,231 systems by the end of 2025 and 870 of the year's 1,721 placements were da Vinci 54.

This facet is rated below the first two and marked narrowing because both of its components are eroding at the edges: patents expire on a schedule, and the 510(k) route is open to anyone who can show equivalence. What is not eroding is the twenty-seven-year head start in evidence and indications.

Grade it on the count of named competitors in the 10-K's competition disclosure — fourteen today5, eight of them Chinese or Asian. The list has been getting longer, which is what a moat made of accumulated engineering looks like when the engineering stops being scarce.

Moat trajectory: Holding steady

More than 5,600 patents and counting, against a regulatory pathway that let two of the largest device companies in the world arrive within eight months of each other. Both halves are exactly where they were.

The number that tests this moat
Reported
Issued patents
More than 5,600

A very large estate protecting refinements of an idea whose foundational patents have expired. Which is why the number that matters more is the next one: fourteen named competitors.

Source: Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 ↗
Aspects of the moat
DIG DEEPER 01
The Patent Wall, and Its Expiry Dates
The company notes in the same paragraph that patents have finite terms, which is why fourteen rivals could enter at all.
DIG DEEPER 02
Class II, Cleared on Substantial Equivalence
The route Intuitive used to reach the market is the route everyone behind it will use to follow.
DIG DEEPER 03
Da Vinci 5 and the Replacement Cycle
Half of last year's placements were the new generation, and it raises the service contract without adding a machine to the base.
DIG DEEPER 04
Ion, and the Second Franchise
Procedures grew 51% while placements fell 28% — a platform being used harder by the hospitals that have it.
⚠ Threats to the moat
⚠ THREAT 01
Fourteen Named Rivals, and Two of Them Are Enormous
Neither Medtronic nor Johnson & Johnson needs robotics to pay for itself in year one.
⚠ THREAT 02
Substantial Equivalence Is a Door, Not a Wall
A competitor does not have to prove its robot is better. It has to show it is equivalent to a da Vinci.
References
  1. ReportedIntuitive owned more than 5,600 patents granted and still in force and more than 2,500 pending worldwide at the end of 2025.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
  2. ReportedIntuitive's products are Class II medical devices cleared under section 510(k) of the Federal Food, Drug, and Cosmetic Act, which requires a manufacturer to demonstrate that its device is "substantially equivalent" to a legally marketed...
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
  3. ReportedThe current expression of it is da Vinci 5, cleared by the FDA in March 2024 for all specialties indicated for da Vinci Xi except cardiac and pediatric, with more than 10,000 times the computing power of its predecessor and force-feedback...
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business (the da Vinci and Ion platforms, instruments with a use count enforced in the instrument itself, training pathways and SimNow, enabling technologies, manufacturing sites, employees by function, and the seasonality of benign procedures) — FY2025 · publ. February 3, 2026 · source ↗
  4. ReportedThe installed base reached 1,231 systems by the end of 2025 and 870 of the year's 1,721 placements were da Vinci 5.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 7 MD&A, business and operating highlights (3,153,000 da Vinci procedures up 18%, 1,721 placements, an installed base of 11,106, utilisation up about 3%, 870 da Vinci 5 placements, Ion procedures and placements, procedures by region and category, and revenue denominated in foreign currencies) — FY2025 · publ. February 3, 2026 · source ↗
  5. ReportedGrade it on the count of named competitors in the 10-K's competition disclosure — fourteen today, eight of them Chinese or Asian.
    Intuitive Surgical Form 10-K, fiscal year ended December 31, 2025 - Item 1 Business: competition, intellectual property and government regulation (the fourteen named competitors, more than 5,600 patents in force and 2,500 pending, Class II devices cleared under section 510(k) on substantial equivalence, special controls, field actions and recalls) — FY2025 · publ. February 3, 2026 · source ↗
Sources
Generated September 23, 2026